Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (3): 273-278.doi: 10.35541/cjd.20200715

• Reviews • Previous Articles     Next Articles

Targeting the JAK-STAT signaling pathway in the treatment of psoriasis

He Xie, Li Yuzhen   

  1. Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China
  • Received:2020-07-14 Revised:2021-02-02 Online:2023-03-15 Published:2023-03-06
  • Contact: Li Yuzhen
  • Supported by:
    National Natural Science Foundation of China(81773320)

Abstract: 【Abstract】 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway is closely related to the occurrence of psoriasis. Various cytokines, including interleukin (IL)-23, IL-22, interferon (IFN)-γ , etc., can promote some key pathologic processes (such as the proliferation and abnormal differentiation of keratinocytes, and infiltration of inflammatory cells) via the JAK-STAT pathway in psoriasis, which suggests that targeting JAK-STAT pathway is a new strategy for the treatment of psoriasis. In recent years, small-molecule JAK inhibitors have shown good efficacy and safety in the treatment of psoriasis, and drugs targeting STAT pathway have been under development, which provide more treatment options for psoriasis. This review summarizes progress in drugs targeting JAK-STAT signaling pathway in the treatment of psoriasis.

Key words: Psoriasis, Janus kinases, STAT transcription factors, Therapy, JAK-STAT pathway, JAK inhibitors, STAT inhibitors